References in periodicals archive ?
and I recognized by 1995 that by using feeder layers with or without LIF would work to successfully maintain isolated human ES cells over an extended period of time.
Finally, what are the implications of so-called "public reason" and "deliberative democracy" for embryo and ES cell debates?
BioTime has discovered that a news release originated overseas reported that BioTime assumed $35,000,000 of debt in acquiring ES Cell International Pte Ltd.
Senator Arlen Specter, who until early June chaired the Senate appropriations subcommittee for NIH and who is a supporter of stem cell research, had asked top NIH officials for their scientific assessment of ES cell research.
At the core of the ES cell issue is the question: when does life begin?
Xcelthera proprietary PluriXcel technology allows efficient derivation of clinical-grade human ES cell lines and direct conversion of such pluripotent human ES cells by small molecule induction into a large commercial scale of high quality human neuronal or heart muscle cells, which constitutes clinically representative progress in both human neuronal and cardiac therapeutic products for treating neurodegenerative and heart diseases.
His new direction eventually took him back to Japan where, armed with the expertise gained at Gladstone, he undertook what seemed to be an impossible undertaking: to find out which genetic factors from among hundreds of possibilities instruct ES cells to become other types of cells.
BioTime will own the stake directly and through its wholly-owned subsidiary ES Cell International Pte Ltd.
In consequence of the ethical difficulties of obtaining fertilised human eggs, numerous ES cell lines have been created.
ESI-035, ESI-049, ESI-051 and ESI-053 were developed by ES Cell International Pte Ltd, a wholly owned subsidiary of BioTime.
Therefore, it would be a feasible alternative to establish pES cell lines for autologous transplantation in females, instead of the ES cell lines from embryos created by somatic cell nuclear transfer with limitations of low success and ethical controversies.
BioTime already held a significant interest in Cell Cure which it acquired through its acquisition of ES Cell International Pte Ltd (ESI) in May 2010.